A promising cancer treatment has been dealt a setback, as the authors of a key paper have reluctantly retracted their report.
Three years ago, Alexander Kugler of the University of Göttingen in Germany and his colleagues described limited success with a new cancer-vaccine strategy in Nature Medicine (SN: 3/4/00, p. 149: Fused cells hold promise of cancer vaccines). The researchers had taken tumor cells from people with kidney cancer, fused them to the patients' own immune cells, and injected the combination back into the patients. In several of the volunteers, this stimulated an immune response against secondary tumors and led to complete remission.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.